Acquired long QT interval syndrome as a predictor of sudden cardiac death: Causes, diagnostic criteria, and management strategy

Despite medical advances in diagnosis and treatment, cardiovascular disease remains the leading cause of death worldwide. Sudden cardiac death, an extreme and irreversible outcome of cardiac arrest, is observed in 50% of cases and is often the first suddenly detected pathology. Long QT syndrome is a variant of electrical heart disease resulting from both congenital and acquired dysfunction and/or regulation of cardiomyocyte ion channels, accompanied by impaired depolarization and repolarization of the ventricular myocardium and characterized by QT prolongation and T abnormalities on the electrocardiogram, clinically accompanied by syncope, bidirectional spindle ventricular tachycardia of the “pirouette” type (torsade de pointes), associated with a high risk of sudden cardiac death or sudden arrhythmic death syndrome. Effective management of these patients requires an individualized approach: careful examination, calculation of corrected QT, determination of typology (hereditary or acquired syndrome), risk assessment using the Tisdale scale, and selection of optimal therapy. Treatment should be comprehensive and include pharmacological (beta-adrenergic blockers, correction of electrolyte balance) and surgical (implantable cardioverter-defibrillator and left-sided thoracic sympathetic denervation of the heart), lifestyle (avoidance of drugs that contribute to prolongation of the QT interval, avoidance of specific arrhythmia triggers (active swimming, exposure to loud noises)) and regular consultation with a cardiologist. Early diagnosis and a comprehensive approach are key to successful prevention of sudden cardiac death in patients with Long QT syndrome.

1. Лебедев ДС, Михайлов ЕН, Неминущий НМ, Голухова ЕЗ. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть: клинические рекомендации. 2020. Режим доступа: https://cr.minzdrav.gov.ru/schema/569_1.

2. Shah SR, Park K, Alweis R. Long QT Syndrome: A Comprehensive Review of the Literature and Current Evidence. Curr Probl Cardiol. 2019;44(3):92–106. https://doi.org/10.1016/j.cpcardiol.2018.04.002.

3. Wallace E, Howard L, Liu M, O’Brien T, Ward D, Shen S, Prendiville T. Long QT Syndrome: Genetics and Future Perspective. Pediatr Cardiol. 2019;40(7):1419–1430. https://doi.org/10.1007/s00246-019-02151-x.

4. Zeppenfeld K, Tfelt-Hansen J, De Riva M, Winkel BG, Behr ER, Blom NA et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. https://doi.org/10.1093/eurheartj/ehac262.

5. Uryasiev OM, Zhukova LA, Glotov SI, Alekseeva EA, Maksimtseva EA. QT interval prolongation and shortening as predictors of sudden cardiac death. Zemsky Physician. 2020;(1):27–32. (In Russ.) Available at: https://cyberleninka.ru/article/n/udlinenie-i-ukorochenie-intervala-qtprediktory-vnezapnoy-serdechnoy-smerti.

6. Marijon E, Uy-Evanado A, Dumas F, Karam N, Reinier K, Teodorescu C et al. Warning Symptoms Are Associated With Survival From Sudden Cardiac Arrest. Ann Intern Med. 2016;164(1):23–29. https://doi.org/10.7326/M14-2342.

7. Ågesen FN, Lynge TH, Blanche P, Banner J, Prescott E, Jabbari R, TfeltHansen J. Temporal trends and sex differences in sudden cardiac death in the Copenhagen City Heart Study. Heart. 2021;107(16):1303–1309. https://doi.org/10.1136/heartjnl-2020-318881.

8. Samorodskaya IV, Bubnova MG, Akulova OA, Ostroushko NI, Drapkina OM. Mortality rates from acute forms of coronary heart disease and sudden cardiac death in the regions of the Russian Federation in 2019–2021. Cardiovascular Therapy and Prevention. 2023;22(5):3557. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3557.

9. van der Werf C, Hendrix A, Birnie E, Bots ML, Vink A, Bardai A et al. Improving usual care after sudden death in the young with focus on inherited cardiac diseases (the CAREFUL study): a community-based intervention study. Europace. 2016;18(4):592–601. https://doi.org/10.1093/europace/euv059.

10. Al-Akchar M, Siddique MS. Long QT syndrome. StatPearls – NCBI Bookshelf; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK441860.

11. Itoh H, Crotti L, Aiba T, Spazzolini C, Denjoy I, Fressart V et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J. 2016;37(18):1456–1464. https://doi.org/10.1093/eurheartj/ehv695.

12. Ostroumova OD, Goloborodova IV. Effect of certain groups of drugs on the risk of QT interval prolongation. Consilium Medicum. 2019;21(10):95–106. (In Russ.) https://doi.org/10.26442/20751753.2019.10.190447.

13. Koide T, Shiba M, Tanaka K, Muramatsu M, Ishida S, Kondo Y, Watanabe K. Severe QT interval prolongation associated with moxifloxacin: a case report. Cases J. 2008;1(1):409. https://doi.org/10.1186/1757-1626-1-409.

14. Hartigan-Go K, Bateman DN, Daly AK, Thomas SH. Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther. 1996;60(1):89–98. https://doi.org/10.1016/S0009-9236(96)90171-X.

15. Kho J, Ioannou A, Mandal AKJ, Cox A, Nasim A, Metaxa S, Missouris CG. Long term use of donepezil and QTc prolongation. Clin Toxicol (Phila). 2021;59(3):208–214. https://doi.org/10.1080/15563650.2020.1788054.

16. Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452–458. https://doi.org/10.1136/postgradmedj-2020-138661.

17. Leonova MV. Drug-induced arrhythmias. Meditsinskiy Sovet. 2020;(21):26–40. (In Russ.) https://doi.org/10.21518/2079-701X-2020-21-26-40.

18. Ohtani H, Taninaka C, Hanada E, Kotaki H, Sato H, Sawada Y, Iga T. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother. 2000;44(10):2630–2637. https://doi.org/10.1128/AAC.44.10.2630-2637.2000.

19. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, Rajagopalan B. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233. https://doi.org/10.1161/CIR.0000000000000905.

20. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology Foundation/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272–e391. https://doi.org/10.1161/CIR.0000000000000549.

21. Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes. J Am Coll Cardiol. 2016;67(13):1639–1650. https://doi.org/10.1016/j.jacc.2015.12.063.

22. Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J Physiol. 2016;594(9):2459–2468. https://doi.org/10.1113/JP270526.

23. Yang T, Chun YW, Stroud DM, Mosley JD, Knollmann BC, Hong C, Roden DM. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation. 2014;130(3):224–234. https://doi.org/10.1161/CIRCULATIONAHA.113.007765.

24. Ostroumova OD, Goloborodova IV. Drug-induced tachycardia of “pirouette” type. Farmateka. 2019;26(9):11–20. (In Russ.) https://doi.org/10.18565/pharmateca.2019.9.11-20.

25. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace. 2014;16(1):101–108. https://doi.org/10.1093/europace/eut214.

26. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl. 2001;3(Suppl. K):K70–K80. https://doi.org/10.1016/S1520-765X(01)90009-4.

27. Motta I, Cozzi SN, Pontali E. QT prolongation for old and new drugs: how much should we really worry? Int J Tuberc Lung Dis. 2022;26(4):298–301. https://doi.org/10.5588/ijtld.22.0072.

28. Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT Interval Prolongation Mechanisms and Clinical Management. Ther Adv Drug Safe. 2012;5(3):241–253. https://doi.org/10.1177/2042098612454283.

29. Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719–1726. https://doi.org/10.1185/03007995.2013.840568.

30. Heemskerk CPM, Pereboom M, van Stralen K, Berger FA, van den Bemt PMLA, Kuijper AFM et al. Risk factors for QTc interval prolongation. Eur J Clin Pharmacol. 2018;74(2):183–191. https://doi.org/10.1007/s00228-017-2381-5.

31. Tooley J, Ouyang D, Hadley D, Turakhia M, Wang P, Ashley E et al. Comparison of QT Interval Measurement Methods and Correction Formulas in Atrial Fibrillation. Am J Cardiol. 2019;123(11):1822–1827. https://doi.org/10.1016/j.amjcard.2019.02.057.

32. Bazett HC. An Analysis of the Time-Relations of Electrocardiograms. Heart. 1920;(7):353–370. Available at: https://www.scirp.org/reference/ReferencesPapers?ReferenceID=1311334.

33. Fridericia LS. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken. Acta Med Scand. 1920;(53):469–486. https://doi.org/10.1111/j.0954-6820.1920.tb18266.x.

34. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70(7):797–801. https://doi.org/10.1016/0002-9149(92)90562-d.

35. Hodges M, Salerno D, Erlien D, Bazett’s. QT correction reviewed. Evidence that a linear QT correction for heart is better. J Am Coll Cardiol. 1983;(1):694.

36. Rautaharju PM, Mason JW, Akiyama T. New age- and sex-specific criteria for QT prolongation based on rate correction formulas that minimize bias at the upper normal limits. Int J Cardiol. 2014;174(3):535–540. https://doi.org/10.1016/j.ijcard.2014.04.133.

37. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is “normal”. J Cardiovasc Electrophysiol. 2006;17(3):333–336. https://doi.org/10.1111/j.1540-8167.2006.00408.x.

38. Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, Kovacs RJ. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479–487. https://doi.org/10.1161/CIRCOUTCOMES.113.000152.

39. Tisdale JE, Jaynes HA, Kingery JR, Overholser BR, Mourad NA, Trujillo TN, Kovacs RJ. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2014;7(3):381–390. https://doi.org/10.1161/CIRCOUTCOMES.113.000651.

40. Vitsenya MV, Ageev F, Gilyarov MJ, Ovchinnikov AG, Orlova RV, Poltavskaya MG. Practical recommendations on correction of cardiovascular toxicity of antitumor drug therapy. Malignant Tumors. 2021;11(3 Suppl.):78–98. (In Russ.) https://doi.org/10.18027/2224-5057-2021-11-3s2-41.

41. Thiruvenkatarajan V, Lee JY, Sembu M, Watts R, Van Wijk RM. Effects of esmolol on QTc interval changes during tracheal intubation: a systematic review. BMJ Open. 2019;9(4):e028111. https://doi.org/10.1136/bmjopen-2018-028111.